Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 4
1992 6
1993 50
1994 67
1995 81
1996 104
1997 129
1998 116
1999 116
2000 100
2001 87
2002 99
2003 125
2004 83
2005 112
2006 111
2007 98
2008 94
2009 120
2010 115
2011 114
2012 113
2013 125
2014 123
2015 152
2016 138
2017 147
2018 155
2019 160
2020 147
2021 143
2022 88
Text availability
Article attribute
Article type
Publication date

Search Results

3,085 results
Results by year
Filters applied: . Clear all
Page 1
A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, Morrow PK, Allcott K, Lyman GH. Dale DC, et al. Support Care Cancer. 2018 Jan;26(1):7-20. doi: 10.1007/s00520-017-3854-x. Epub 2017 Sep 22. Support Care Cancer. 2018. PMID: 28939926 Free PMC article. Review.
PURPOSE: Filgrastim (NEUPOGEN()) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing neutropenia-related infections and mobilizing hematopoietic stem cells. ...CONCLUSIONS: This systematic literature review and meta-analysis …
PURPOSE: Filgrastim (NEUPOGEN()) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing …
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO; American Society of Clinical Oncology. Smith TJ, et al. J Clin Oncol. 2015 Oct 1;33(28):3199-212. doi: 10.1200/JCO.2015.62.3488. Epub 2015 Jul 13. J Clin Oncol. 2015. PMID: 26169616 Review.
RESULTS: Changes to previous recommendations include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the recommendation regarding routine use of CSFs in older patients with diffuse aggressive lymphoma, and addition of recommendations against routin …
RESULTS: Changes to previous recommendations include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the rec …
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell MA, Zweizig SL, Warshal DP, Hanjani P, Carney ME, Huang H, Cella D, Zaino R, Fleming GF. Miller DS, et al. J Clin Oncol. 2020 Nov 20;38(33):3841-3850. doi: 10.1200/JCO.20.01076. Epub 2020 Sep 29. J Clin Oncol. 2020. PMID: 33078978 Free PMC article. Clinical Trial.
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V. Aapro M, et al. Support Care Cancer. 2017 Nov;25(11):3295-3304. doi: 10.1007/s00520-017-3842-1. Epub 2017 Aug 25. Support Care Cancer. 2017. PMID: 28842778 Free PMC article. Review.
Current guidelines provide recommendations on granulocyte colony-stimulating factors (G-CSF) for prevention of FN, but guidance is unclear regarding use of short- vs long-acting G-CSF (e.g., filgrastim vs pegfilgrastim/lipegfilgrastim, respectively). An international panel …
Current guidelines provide recommendations on granulocyte colony-stimulating factors (G-CSF) for prevention of FN, but guidance is unclear r …
Science of Biosimilars.
Harvey RD. Harvey RD. J Oncol Pract. 2017 Sep;13(9_suppl):17s-23s. doi: 10.1200/JOP.2017.026062. J Oncol Pract. 2017. PMID: 28898589 Review.
Postmarketing surveillance programs will be required to evolve and ensure optimal pharmacovigilance reporting, because the potential for unexpected adverse events with biosimilars is higher than with conventional generic agents as a result of different manufacturing processes and …
Postmarketing surveillance programs will be required to evolve and ensure optimal pharmacovigilance reporting, because the potential for une …
Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.
Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J, Jiang M, Bai H, Lang T, Wang J, Liu L, Yang T, Huang X, Liu F, Lou S, Liu Y, Zhang C, Liu H, Gao L, Liu J, Zhu L, Wen Q, Chen T, Wang P, Rao J, Mao M, Wang C, Duan X, Luo L, Peng X, Cassady K, Zhong JF, Zhang X. Gao L, et al. J Clin Oncol. 2020 Dec 20;38(36):4249-4259. doi: 10.1200/JCO.19.03277. Epub 2020 Oct 27. J Clin Oncol. 2020. PMID: 33108244 Free PMC article. Clinical Trial.
Intrauterine G-CSF Administration in Recurrent Implantation Failure (RIF): An Rct.
Kalem Z, Namli Kalem M, Bakirarar B, Kent E, Makrigiannakis A, Gurgan T. Kalem Z, et al. Sci Rep. 2020 Mar 20;10(1):5139. doi: 10.1038/s41598-020-61955-7. Sci Rep. 2020. PMID: 32198409 Free PMC article. Clinical Trial.
The procedure was performed by administering 30 mIU of Leucostim(Filgrastim [G-CSF] 30 mIU/mL; DEM Medical, Dong-A; South Korea) through slow infusion into the endometrial cavity using a soft embryo transfer catheter. ...
The procedure was performed by administering 30 mIU of Leucostim(Filgrastim [G-CSF] 30 mIU/mL; DEM Medical, Dong-A; South Korea) thro …
Filgrastim induced thrombocytopenia.
Kango G, Haroun F. Kango G, et al. BMJ Case Rep. 2020 Jun 30;13(6):e234584. doi: 10.1136/bcr-2020-234584. BMJ Case Rep. 2020. PMID: 32606115 Free PMC article.
The diagnosis is ascertained when there is reproducibility of thrombocytopenia with repeated exposure. Filgrastim is used during peripheral blood progenitor cell harvest during autologous stem cell transplantation in the setting of multiple myeloma to prolong event-free su …
The diagnosis is ascertained when there is reproducibility of thrombocytopenia with repeated exposure. Filgrastim is used during peri …
Tbo-Filgrastim: A Review in Neutropenic Conditions.
Blair HA, Scott LJ. Blair HA, et al. BioDrugs. 2016 Apr;30(2):153-60. doi: 10.1007/s40259-016-0172-7. BioDrugs. 2016. PMID: 27023705 Review.
Tbo-filgrastim was generally well tolerated, with a similar safety profile to that of reference filgrastim. ...Current evidence indicates that tbo-filgrastim is a useful alternative to reference filgrastim in patients requiring filgrastim therap …
Tbo-filgrastim was generally well tolerated, with a similar safety profile to that of reference filgrastim. ...Current evidenc …
Zarxio--a filgrastim biosimilar.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2016 Mar 14;58(1490):34-5. Med Lett Drugs Ther. 2016. PMID: 26963154 Review. No abstract available.
3,085 results